Aquinox Pharmaceuticals Inc.

The momentum for this stock is not very good. Aquinox Pharmaceuticals Inc. is not a good value stock. Aquinox Pharmaceuticals Inc. is a mediocre stock to choose.

News

Neoleukin Therapeutics Stock Set to Reverse Split on Tuesday, December 19th (NASDAQ:NLTX)

Zolmax Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX Free Report) are set to reverse split before the market opens on Tuesday, December 19th. The 1-4 reverse split was announced on Tuesday...\n more…

Neoleukin Therapeutics announces 1-for-4 reverse stock split

SeekingAlpha.com: All News Neoleukin Therapeutics approves a 1-for-4 reverse stock split to comply with Nasdaq's minimum bid price requirement.\n more…

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Neoleukin Therapeutics (NASDAQ:NLTX) Shares Scheduled to Reverse Split on Monday, September 25th

Ticker Report Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX Free Report) are scheduled to reverse split on Monday, September 25th. The 1-5 reverse split was announced on Friday, September 22nd. The...\n more…

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

Globe Newswire SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin or the Company (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics...\n more…

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares Acquired by US Bancorp DE

Zolmax US Bancorp DE boosted its position in shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX Free Report) by 111.2% during the first quarter, according to the company in its most recent Form...\n more…